Teleflex names Jason Weidman as CEO, replacing interim chief effective June 8

Filed April 30, 2026 · Period ending April 28, 2026 · ~1 min read

Key Changes

• high

  Jason Weidman, 51, appointed President and CEO effective June 8, 2026, replacing interim CEO Stuart Randle. Weidman joins from Medtronic where he led Coronary, Renal Denervation, Aortic, Peripheral and Venous divisions after 20 years with the company.

  Item 5.02 verify on EDGAR →
• medium

  New CEO receives $1M base salary, 125% target bonus (guaranteed at prorated target for 2026), and $7M annual equity awards starting 2027. Sign-on package includes $7M restricted stock (4-year vest) and $1M stock options (3-year vest).

  Item 5.02 verify on EDGAR →
• medium

  Change-of-control severance provides 36 months pay, 300% target bonus, and full equity acceleration if terminated without cause or resigns for good reason following acquisition—creating potential shareholder obligations in M&A scenarios.

  Item 5.02 verify on EDGAR →